Jason Cobb, MD
Nephrology · Atlanta, GANPI 1407026818
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,093 of the $5,941 with a category attached, or 85.7%. 9 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 43.3% of the total. Reporting peaked in 2020 at $2,573 and has fallen 97.3% since, to $71 in 2025.
Across 31 payments — averaging $191.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Vertex$1K
- GSK$920
- Travere Therapeutics, Inc.$480
- Aurinia Pharma U.S., Inc.$426
- Ardelyx, Inc.$144
- plus $200 from 3 others
Across 2 payments — averaging $29,756 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$38K
- Aurinia Pharma U.S., Inc.$21K
What the payments were for
- Consulting fees$5,09386%
- Food & beverage$76913%
- Education$801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $2,573 |
| Vertex | 1 | $1,200 |
| GSK | 1 | $920 |
| Travere Therapeutics, Inc. | 18 | $480 |
| Aurinia Pharma U.S., Inc. | 5 | $426 |
| Ardelyx, Inc. | 1 | $144 |
| Novo Nordisk | 2 | $135 |
| Calliditas Therapeutics US Inc. | 1 | $56 |
| Akebia Therapeutics Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,941 in reported general payments places this provider in the 80th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LupkynisVoclosporin | 15 | $169,525 |
| LokelmaSodium Zirconium Cyclosilicate | 42 | $32,113 |
| Mycophenolate Mofetil | 46 | $7,951 |
| Clonidine | 21 | $4,385 |
| Sevelamer Carbonate | 30 | $3,843 |
| Midodrine Hcl | 23 | $3,813 |
| Nifedipine ErNifedipine | 102 | $3,406 |
| Calcium Acetate | 20 | $1,499 |
| Hydralazine Hcl | 79 | $987 |
| Torsemide | 39 | $780 |
| Esomeprazole Magnesium | 16 | $776 |
| Valsartan | 19 | $755 |
| Carvedilol | 116 | $746 |
| Gabapentin | 48 | $641 |
| Potassium Chloride | 42 | $616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aurinia Pharma U.S., Inc.Lupkynis | $426 | $169,52515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 nephrology providers in Georgia.
Other nephrology in Atlanta
- Sheldon ShoreAtlanta$474K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Frederic Rahbari OskouiAtlanta$88K
- Tarik LalwaniAtlanta$69K
- Haimanot WasseAtlanta$60K
- Janice LeaAtlanta$21K
- Vandana NiyyarAtlanta$11K
- Gautham ViswanathanAtlanta$10K
- Lara WatkinsAtlanta$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.